Neurocrine Biosciences INC Form 4 insider transactions
NASDAQ
Chief Financial Officer of Neurocrine Biosciences, Matt Abernethy, reports acquisition and disposition of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting.
NASDAQ
Chief Human Resources Officer Julie Cooke of Neurocrine Biosciences reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged trading plan.
NASDAQ
Director Kevin Gorman reports the vesting of restricted stock units and the sale of Neurocrine Biosciences (NBIX) stock under a pre-arranged 10b5-1 trading plan.
NASDAQ
Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.
NASDAQ
Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, reported the vesting of restricted stock units and the sale of common stock under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Form 4: Neurocrine Biosciences CEO Kyle Gano Executes Stock Option and Sells Shares Under 10b5-1 Plan
Neurocrine Biosciences CEO Kyle Gano exercised stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.
NASDAQ
David Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.
NASDAQ
Chief Commercial Officer Eric Benevich of Neurocrine Biosciences reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.
NASDAQ
Chief Financial Officer of Neurocrine Biosciences, Matt Abernethy, reports the acquisition and disposition of common stock and restricted stock units.
NASDAQ
Julie Cooke, Chief Human Resources Officer of Neurocrine Biosciences, reported the vesting of restricted stock units and subsequent sale of shares under pre-arranged trading plans.
NASDAQ
Director Kevin Gorman exercised stock options and sold shares of Neurocrine Biosciences (NBIX) under a pre-arranged 10b5-1 trading plan.
NASDAQ
Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged trading plan.
NASDAQ
Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.
NASDAQ
Form 4: Neurocrine Biosciences Chief Legal Officer Darin Lippoldt Reports Stock Sale and RSU Vesting
Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.
NASDAQ
Form 4: Neurocrine Biosciences CEO Kyle Gano Executes Stock Option and Sells Shares Under 10b5-1 Plan
Neurocrine Biosciences CEO Kyle Gano exercised stock options and sold shares of common stock on January 31, 2025, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, reports the acquisition and disposal of common stock and restricted stock units (RSUs) on January 31, 2025, and February 3, 2025, under a pre-arranged trading plan.
NASDAQ
David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged trading plan.
NASDAQ
Chief Commercial Officer Eric Benevich of Neurocrine Biosciences reports the sale of 1,207 shares of common stock under a pre-arranged 10b5-1 trading plan.
NASDAQ
Matt Abernethy, CFO of Neurocrine Biosciences, reports the acquisition and disposal of common stock and restricted stock units on January 31, 2025, according to a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Director Kevin Gorman exercised stock options and sold shares of Neurocrine Biosciences (NBIX) on January 27, 2025, according to a Form 4 filing with the SEC.
NASDAQ
Form 4: Neurocrine Biosciences CEO Kyle Gano Executes Stock Options and Sells Shares Under 10b5-1 Plan
Neurocrine Biosciences CEO Kyle Gano exercised stock options and sold shares of common stock on January 15, 2025, under a pre-arranged 10b5-1 trading plan.
NASDAQ
Neurocrine Biosciences' Chief Regulatory Officer, Ingrid Delaet, executed stock options and sold shares according to a pre-arranged 10b5-1 trading plan.
NASDAQ
Form 4: Neurocrine Biosciences Chief Medical Officer Receives Stock Options and Restricted Stock Units
Neurocrine Biosciences' Chief Medical Officer, Eiry Roberts, was granted stock options and restricted stock units as part of their compensation.
NASDAQ
Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares of common stock on December 17, 2024, according to a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, exercised stock options and sold shares under a pre-arranged trading plan.
NASDAQ
Neurocrine Biosciences' Chief Medical Officer, Eiry Roberts, exercised stock options, acquiring a total of 7,345 shares of common stock at various prices.
NASDAQ
Director Stephen Sherwin of Neurocrine Biosciences donated 2,000 shares of common stock to a charitable organization on November 4, 2024.
NASDAQ
Neurocrine Biosciences CEO Kyle Gano reports acquisition of restricted stock units and stock options.
NASDAQ
David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, sold 1,295 shares of common stock at $113.66 per share under a pre-arranged 10b5-1 trading plan.
NASDAQ
David W. Boyer, Chief Corporate Affairs Officer of Neurocrine Biosciences, sold 3,461 shares of common stock at an average price of $121.8804 under a pre-arranged 10b5-1 trading plan.